First-In-Human, Phase 1, Randomized, Dose-Escalation Trial with Recombinant Anti-IL-20 Monoclonal Antibody in Patients with Psoriasis

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Gottlieb, Alice B ^a,b   Krueger, James G ^c,d   Lundblad, Mia Sandberg ^e,f   Gothberg, Marie ^a,b,c   Skolnick, Brett E ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ROCKEFELLER UNIVERSITY   (United States)

^d NOVO NORDISK A S   (Denmark)

^e NOVO NORDISK INC   (United States)

^f DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 20; MONOCLONAL ANTIBODY; NNC 01090012; PLACEBO; UNCLASSIFIED DRUG; URIC ACID; FLETIKUMAB; INTERLEUKIN DERIVATIVE; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CELLULITIS; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEADACHE; HUMAN; HYPERURICEMIA; MALE; MORNING DOSAGE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OROPHARYNX PAIN; PHASE 1 CLINICAL TRIAL; PRURITUS; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SINGLE DRUG DOSE; STEADY STATE; TREATMENT DURATION; URIC ACID BLOOD LEVEL; CLINICAL TRIAL; DOSE RESPONSE; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INTERLEUKINS; MALE; MIDDLE AGED; PSORIASIS; RECOMBINANT PROTEINS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84941991984     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0134703     Document Type: Article

References (32)

1. Lebwohl M. Psoriasis. Lancet. 2003; 361(9364):1197-204.
2. Asadullah K, Volk HD, Sterry W. Novel immunotherapies for psoriasis. Trends Immunol. 2002; 23 (1):47-53.
3. Gottlieb AB. Psoriasis: emerging therapeutic strategies. Nat Rev Drug Discov. 2005; 4(1):19-34.
4. Gelfand JM, Stern RS, Nijsten T, Feldman SR, Thomas J, Kist J, et al. The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol. 2005; 52(1):23-6.
5. Robinson D Jr, Hackett M, Wong J, Kimball AB, Cohen R, Bala M, et al. Co-occurrence and comorbidities in patients with immune-mediated inflammatory disorders: an exploration using US healthcare claims data, 2001-2002. Curr Med Res Opin. 2006; 22(5):989-1000.
6. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004; 9(2):136-9.
7. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol. 2009; 60(2):218-24. doi: 10.1016/j.jaad.2008. 09.022
8. Icen M, Crowson CS, McEvoy MT, Dann FJ, Gabriel SE, Maradit Kremers H. Trends in incidence of adult-onset psoriasis over three decades: a population-based study. J Am Acad Dermatol. 2009; 60 (3):394-401. doi: 10.1016/j.jaad.2008.10.062
9. Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Arch Intern Med. 2007; 167(15):1670-5.
10. Novartis announces FDA approval for first IL-17A antagonist Cosentyx (secukinumab) for moderate-tosevere plaque psoriasis patients 2015. Available: http://www.novartis.com/newsroom/media-releases/en/2015/1888645.shtml. Accessed: 12 March 2015.
11. Leman J, Burden AD. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis. Br J Dermatol. 2012; 167 suppl 3:12-20. doi: 10.1111/j.1365-2133.2012.11209.x
12. Hofmann SR, Rosen-Wolff A, Tsokos GC, Hedrich CM. Biological properties and regulation of IL-10 related cytokines and their contribution to autoimmune disease and tissue injury. Clin Immunol. 2012; 143(2):116-27. doi: 10.1016/j.clim.2012.02.005
13. Kunz S, Wolk K, Witte E, Witte K, Doecke WD, Volk HD, et al. Interleukin (IL)-19, IL-20 and IL-24 are produced by and act on keratinocytes and are distinct from classical ILs. Exp Dermatol. 2006; 15 (12):991-1004.
14. Romer J, Hasselager E, Norby PL, Steiniche T, Thorn Clausen J, Kragballe K. Epidermal overexpression of interleukin-19 and-20 mRNA in psoriatic skin disappears after short-term treatment with cyclosporine a or calcipotriol. J Invest Dermatol. 2003; 121(6):1306-11.
15. Wei CC, Chen WY, Wang YC, Chen PJ, Lee JY, Wong TW, et al. Detection of IL-20 and its receptors on psoriatic skin. Clin Immunol. 2005; 117(1):65-72.
16. Otkjaer K, Kragballe K, Funding AT, Clausen JT, Noerby PL, Steiniche T, et al. The dynamics of gene expression of interleukin-19 and interleukin-20 and their receptors in psoriasis. Br J Dermatol. 2005; 153(5):911-8.
17. Wolk K, Witte K, Witte E, Proesch S, Schulze-Tanzil G, Nasilowska K, et al. Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. J Leukoc Biol. 2008; 83(5):1181-93. doi: 10.1189/jlb.0807525
18. Wolk K, Kunz S, Asadullah K, Sabat R. Cutting edge: immune cells as sources and targets of the IL-10 family members? J Immunol. 2002; 168(11):5397-402.
19. Sa SM, Valdez PA, Wu J, Jung K, Zhong F, Hall L, et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol. 2007; 178(4):2229-40.
20. Dumoutier L, Leemans C, Lejeune D, Kotenko SV, Renauld JC. Cutting edge: STAT activation by IL-19, IL-20 and mda-7 through IL-20 receptor complexes of two types. J Immunol. 2001; 167(7):3545-9.
21. Wolk K, Haugen HS, Xu W, Witte E, Waggie K, Anderson M, et al. IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. J Mol Med (Berl). 2009; 87 (5):523-36.
22. Blumberg H, Conklin D, Xu WF, Grossmann A, Brender T, Carollo S, et al. Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell. 2001; 104(1):9-19.
23. Tohyama M, Hanakawa Y, Shirakata Y, Dai X, Yang L, Hirakawa S, et al. IL-17 and IL-22 mediate IL-20 subfamily cytokine production in cultured keratinocytes via increased IL-22 receptor expression. Eur J Immunol. 2009; 39(10):2779-88. doi: 10.1002/eji.200939473
24. Stenderup K, Rosada C, Worsaae A, Dagnaes-Hansen F, Steiniche T, Hasselager E, et al. Interleukin-20 plays a critical role in maintenance and development of psoriasis in the human xenograft transplantation model. Br J Dermatol. 2009; 160(2):284-96. doi: 10.1111/j.1365-2133.2008.08890.x
25. Lundblad MS, Overgaard RV, Gothberg M, Fjording MS, Watson E. Clinical pharmacokinetics of the anti-interleukin-20 monoclonal antibody NNC0109-0012 in healthy volunteers and patients with psoriasis or rheumatoid arthritis. Adv Ther. 2015; 32(3):228-38. doi: 10.1007/s12325-015-0191-7
26. World Medical Association. Declaration of Helsinki-Ethical Principles for Medical Research Involving Human Subjects 2004. Available: http://www.wma.net/en/30publications/10policies/b3/. Accessed: 10 February 2014.
27. International Conference on Harmonisation. ICH Harmonised Tripartite Guideline. Good Clinical Practice. 01 May 1996.
28. Robinson A, Kardos M, Kimball AB. Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. J Am Acad Dermatol. 2012; 66(3):369-75. doi: 10. 1016/j.jaad.2011.01.022
29. Puzenat E, Bronsard V, Prey S, Gourraud PA, Aractingi S, Bagot M, et al. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. J Eur Acad Dermatol Venereol. 2010; 24 Suppl 2:10-6. doi: 10.1111/j.1468-3083.2009.03562.x
30. Wang F, Smith N, Maier L, Xia W, Hammerberg C, Chubb H, et al. Etanercept suppresses regenerative hyperplasia in psoriasis by acutely downregulating epidermal expression of interleukin (IL)-19, IL-20 and IL-24. Br J Dermatol. 2012; 167(1):92-102. doi: 10.1111/j.1365-2133.2012.10961.x
31. Garcia-Perez ME, Jean J, Pouliot R. Antipsoriatic drug development: challenges and new emerging therapies. Recent Pat Inflamm Allergy Drug Discov. 2012; 6(1):3-21.
32. Wang L, Li K, Xu Q, Chen X, Xue F, Shi R, et al. Potential synergy between SNP and CpG-A or IL-1beta in regulating transcriptional activity of IL-20 promoter. J Invest Dermatol. 2014; 134(2):389-95. doi: 10.1038/jid.2013.314